Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and PathAI, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and AI pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
A week ago, Quest Diagnostics Incorporated ( NYSE:DGX ) came out with a strong set of first-quarter numbers that could...
Comprehensive SWOT Analysis: Quest Diagnostics Inc's Financial and Strategic Position